Onyx Pharmaceuticals Inc. (ONXX): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Onyx Pharmaceuticals ( ONXX) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.7%. By the end of trading, Onyx Pharmaceuticals fell $3.81 (-2.9%) to $128.21 on heavy volume. Throughout the day, 6,377,107 shares of Onyx Pharmaceuticals exchanged hands as compared to its average daily volume of 1,839,900 shares. The stock ranged in price between $127.65-$132.98 after having opened the day at $131.86 as compared to the previous trading day's close of $132.02. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 40.6%, Inovio Pharmaceuticals ( INO), down 26.1%, Aastrom Biosciences ( ASTM), down 21.4% and Ambit Biosciences ( AMBI), down 18.3%.

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. Onyx Pharmaceuticals has a market cap of $9.7 billion and is part of the health care sector. Shares are up 74.8% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Onyx Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Onyx Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow.

On the positive front, Opexa Therapeutics ( OPXA), up 131.8%, iBio ( IBIO), up 24.9%, Oxygen Biotherapeutics ( OXBT), up 17.9% and GW Pharmaceuticals PLC ADR ( GWPH), up 15.8% , were all gainers within the drugs industry with Valeant Pharmaceuticals International ( VRX) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%